Pathology & Oncology Research最新文献

{"title":"Indolent T-lymphoblastic proliferation with fibrolamellar hepatocellular carcinoma developed after colorectal adenocarcinoma: a case report.","authors":"Wen Han,&nbsp;Bei Wang,&nbsp;Xiang Yong,&nbsp;Yi Zhang,&nbsp;Mingyu Shao,&nbsp;Chun Wang","doi":"10.3389/pore.2023.1611151","DOIUrl":"https://doi.org/10.3389/pore.2023.1611151","url":null,"abstract":"<p><p><b>Objective:</b> Indolent T-lymphoblastic proliferation (iT-LBP) is a non-neoplastic disease with an indolent clinical course, manifesting as hyperplasia of immature extrathymic T-lymphoblastic cells. Isolated iT-LBP has been observed, but the majority of iT-LBP cases has been seen in conjunction with other diseases. iT-LBP is easily misdiagnosed as T-lymphoblastic lymphoma/leukemia, and understanding the disease of indolent T-lymphoblastic proliferation may prevent misdiagnosis and missed diagnosis in pathological diagnosis. <b>Case presentation:</b> We report a case morphology, immunophenotypic, and molecular features of iT-LBP combined with fibrolamellar hepatocellular carcinoma developed after colorectal adenocarcinoma and review relevant literature. <b>Conclusion:</b> iT-LBP combined with fibrolamellar hepatocellular carcinoma developed after colorectal adenocarcinoma is relatively rare and should always be considered as a differential diagnosis of T-lymphoblastic lymphoma and scirrhous hepatocellular carcinoma as the two disorders show highly similar clinical features.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9605848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor budding as a predictor of disease-free survival in patients with cholangiocarcinoma.","authors":"Kyung Bin Kim,&nbsp;Ji Hyun Ahn,&nbsp;Soon Wook Kwon,&nbsp;Su Ji Lee,&nbsp;Yury Lee,&nbsp;Seo Young Park,&nbsp;Ahrong Kim,&nbsp;Kyung Un Choi,&nbsp;Chang Hun Lee,&nbsp;Gi Yeong Huh","doi":"10.3389/pore.2023.1611216","DOIUrl":"https://doi.org/10.3389/pore.2023.1611216","url":null,"abstract":"<p><p><b>Background:</b> Tumor budding is considered a prognostic factor in several solid cancer types. However, we lack comprehensive information on the importance of tumor budding in cholangiocarcinoma. Therefore, we aimed to assess the prognostic value of tumor budding in intrahepatic and extrahepatic cholangiocarcinomas and to evaluate its correlations with other clinicopathological parameters. <b>Methods:</b> We monitored 219 patients who underwent surgery for intrahepatic or extrahepatic cholangiocarcinoma at the Pusan National University Hospital between 2012 and 2021. Tumor budding was evaluated using the International Tumor Budding Consensus Conference scoring system. Tumor budding was classified into low (0-4), intermediate (5-9), and high (≥10). For statistical analysis, tumor budding was divided into two groups based on the cut-off value of 10 (lower: 0-9 vs. higher: ≥10). The correlations between clinicopathological parameters were examined using the chi-square and Fisher's exact test. The prognostic values of the variables were analyzed using the log-rank test and Cox regression analysis. <b>Results:</b> Low, intermediate, and high tumor buddings were identified in 135 (61.6%), 63 (28.8), and 21 (9.6%), patients, respectively. Higher tumor budding was related to the presence of lymphatic invasion (<i>p</i> = 0.017), higher tumor grade (<i>p</i> = 0.001), higher N category (<i>p</i> = 0.034). In the univariable and multivariable analyses, higher tumor budding was associated with shorter disease-free survival in 97 (44.3%) patients who underwent R0 resection (<i>p</i> < 0.001 and <i>p</i> = 0.011). Tumor budding did not significantly correlate with disease-specific survival in entire patients. <b>Conclusion:</b> Tumor budding may serve as a prognostic factor for intrahepatic and extrahepatic cholangiocarcinomas treated with R0 resection.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9636837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased Kremen2 predicts worse prognosis in colon cancer.","authors":"Junxian Long,&nbsp;Fengyun Cong,&nbsp;Yousheng Wei,&nbsp;Jungang Liu,&nbsp;Weizhong Tang","doi":"10.3389/pore.2023.1611082","DOIUrl":"https://doi.org/10.3389/pore.2023.1611082","url":null,"abstract":"<p><p><b>Background:</b> Colon cancer (CC) is the fifth most prevalent cancer around the globe and poses a major risk to human health. Even though Kremen2 serves as a prognostic indicator in individuals with malignant tumours, its role in evaluating the prognosis of individuals with colon cancer has not been confirmed. <b>Methods:</b> Here, we examined the protein expression of Kremen2 in CC tissues and paired adjacent normal tissues by immunohistochemistry (IHC), then analyzed the clinical and RNA-seq data presented in The Cancer Genome Atlas (TCGA) database to confirm the relationship between Kremen2 levels and CC. In addition, the associations between Kremen2 mRNA expression and infiltrating immune cells were examined. <b>Results:</b> The study showed that the mRNA expression and protein level of Kremen2 were increased in CC tissues compared with adjacent normal tissues. According to Kaplan-Meier analysis, high Kremen2 expression in CC was linked to poor overall survival and progression-free survival. Clinical correlation analysis highlighted that a high level of Kremen2 expression was strongly linked with tumour progression, particularly lymph node metastasis. Cox regression analysis highlighted that Kremen2 was an independent prognostic indicator for CC. Bioinformatic studies highlighted that Kremen2 might be associated with the immune status in CC. <b>Conclusion:</b> Increased Kremen2 could serve as a potential prognostic CC biomarker.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9761965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MDM2 promotes cancer cell survival through regulating the expression of HIF-1α and pVHL in retinoblastoma.","authors":"Shouhua Zhang,&nbsp;Hongyan Xu,&nbsp;Weiming Li,&nbsp;Jianfeng Ji,&nbsp;Qifang Jin,&nbsp;Leifeng Chen,&nbsp;Qiang Gan,&nbsp;Qiang Tao,&nbsp;Yong Chai","doi":"10.3389/pore.2023.1610801","DOIUrl":"https://doi.org/10.3389/pore.2023.1610801","url":null,"abstract":"<p><p>Hypoxia is an important tumor feature and hypoxia-inducible factor 1 (HIF-1) is a master regulator of cell response to hypoxia. Mouse double minute 2 homolog (MDM2) promotes cancer cell survival in retinoblastoma (RB), with the underlying mechanism remaining elusive. In this study, we investigated the role of MDM2 and its relation to HIF-1α in RB. Expression analysis on primary human RB samples showed that MDM2 expression was positively correlated with that of HIF-1α while negatively correlated with von Hippel-Lindau protein (pVHL), the regulator of HIF-1α. In agreement, RB cells with MDM2 overexpression showed increased expression of HIF-1α and decreased expression of pVHL, while cells with MDM2 siRNA knockdown or MDM2-specific inhibitor showed the opposite effect under hypoxia. Further immuno-precipitation analysis revealed that MDM2 could directly interact with pVHL and promotes its ubiquitination and degradation, which consequently led to the increase of HIF-1α. Inhibition of MDM2 and/or HIF-1α with specific inhibitors induced RB cell death and decreased the stem cell properties of primary RB cells. Taken together, our study has shown that MDM2 promotes RB survival through regulating the expression of pVHL and HIF-1α, and targeting MDM2 and/or HIF-1α represents a potential effective approach for RB treatment.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10665459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of pretreatment Controlling Nutritional Status score in esophageal cancer: a meta-analysis.","authors":"Jing Lv,&nbsp;Peirui Chen,&nbsp;Jianqiang Wu,&nbsp;Caihong Hu","doi":"10.3389/pore.2023.1611221","DOIUrl":"https://doi.org/10.3389/pore.2023.1611221","url":null,"abstract":"<p><p><b>Background and purpose:</b> The association between the pretreatment Controlling Nutritional Status (CONUT) score and the prognosis of esophageal cancer patients remains unclear. The aim of this meta-analysis was to further elucidate the prognostic role of the pretreatment CONUT score in esophageal cancer based on current evidence. <b>Methods:</b> The PubMed, Embase, Web of Science and CNKI databases were searched up to 27 September 2022. The primary and secondary outcomes were overall survival (OS) and progression-free survival (PFS)/cancer-specific survival (CSS), and the hazard ratio (HR) and 95% confidence interval (CI) were pooled for analysis. <b>Results:</b> A total of 11 retrospective studies involving 3,783 participants were included. The pooled results demonstrated that a higher pretreatment CONUT score was significantly related to poor OS (HR = 1.82, 95% CI: 1.31-2.54, <i>p</i> < 0.001), and subgroup analysis stratified by pathological type showed similar results. In addition, the pretreatment CONUT score was associated with poor PFS (HR = 1.19, 95% CI: 1.10-1.28, <i>p</i> < 0.001) and CSS (HR = 2.67, 95% CI: 1.77-4.02, <i>p</i> < 0.001). <b>Conclusion:</b> The pretreatment CONUT score was predictive of worse prognosis in esophageal cancer, and patients with a higher CONUT score showed worse survival.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10193740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The roles of NOP56 in cancer and SCA36.","authors":"Shimin Zhao,&nbsp;Dongdong Zhang,&nbsp;Sicheng Liu,&nbsp;Jun Huang","doi":"10.3389/pore.2023.1610884","DOIUrl":"https://doi.org/10.3389/pore.2023.1610884","url":null,"abstract":"<p><p>NOP56 is a highly conserved nucleolar protein. Amplification of the intron GGCCTG hexanucleotide repeat sequence of the <i>NOP56</i> gene results in spinal cerebellar ataxia type 36 (SCA36). NOP56 contains an N-terminal domain, a coiled-coil domain, and a C-terminal domain. Nucleolar protein NOP56 is significantly abnormally expressed in a number of malignant tumors, and its mechanism is different in different tumors, but its regulatory mechanism in most tumors has not been fully explored. NOP56 promotes tumorigenesis in some cancers and inhibits tumorigenesis in others. In addition, NOP56 is associated with methylation in some tumors, suggesting that NOP56 has the potential to become a tumor-specific marker. This review focuses on the structure, function, related signaling pathways, and role of NOP56 in the progression of various malignancies, and discusses the progression of NOP56 in neurodegenerative and other diseases.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10665457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High prevalence of Wilms tumor 1 expression in multiple myeloma and plasmacytoma: A cohort of 142 Asian patients' samples.","authors":"Ployploen Phikulsod,&nbsp;Sanya Sukpanichnant,&nbsp;Chutima Kunacheewa,&nbsp;Thaweesak Chieochansin,&nbsp;Mutita Junking,&nbsp;Pa-Thai Yenchitsomanus","doi":"10.3389/pore.2023.1610844","DOIUrl":"https://doi.org/10.3389/pore.2023.1610844","url":null,"abstract":"<p><p>Wilms tumor 1 (WT1) is a promising target antigen for cancer immunotherapy. However, WT1 protein expression and its clinical correlation in multiple myeloma (MM) patients are still limited. We, therefore, investigated WT1 expression in 142 bone marrow and plasmacytoma samples of MM patients at different stages of the disease by immunohistochemistry. The correlations between WT1 expression and clinical parameters or treatment outcomes were evaluated. The overall positive rate of WT1 expression was 91.5%; this high prevalence was found in both bone marrow and plasmacytoma samples, regardless of the disease status. Cytoplasmic WT1 expression was correlated with high serum free light chain ratio at presentation. However, no significant association between WT1 expression and treatment outcome was observed. This study confirms the high prevalence of WT1 expression in an Asian cohort of MM, encouraging the development of immunotherapy targeting WT1 in MM patients, particularly in those with extramedullary plasmacytoma or relapsed disease.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10692325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.","authors":"Christopher T Boniface,&nbsp;Paul T Spellman","doi":"10.3389/pore.2023.1611133","DOIUrl":"https://doi.org/10.3389/pore.2023.1611133","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/pore.2022.1610103.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9314844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC.","authors":"Anke Behnke,&nbsp;Anne Cayre,&nbsp;Giovanna De Maglio,&nbsp;Giuseppe Giannini,&nbsp;Lionel Habran,&nbsp;Marina Tarsitano,&nbsp;Massimiliano Chetta,&nbsp;David Cappellen,&nbsp;Alexandra Lespagnol,&nbsp;Cecile Le Naoures,&nbsp;Gabriella Massazza,&nbsp;Annarita Destro,&nbsp;Irina Bonzheim,&nbsp;Achim Rau,&nbsp;Achim Battmann,&nbsp;Bettina Kah,&nbsp;Emmanuel Watkin,&nbsp;Michael Hummel","doi":"10.3389/pore.2023.1610707","DOIUrl":"https://doi.org/10.3389/pore.2023.1610707","url":null,"abstract":"<p><p>Accurate testing for epidermal growth factor receptor (<i>EGFR</i>) variants is essential for informing treatment decisions in non-small cell lung cancer (NSCLC). Automated diagnostic workflows may allow more streamlined initiation of targeted treatments, where appropriate, while comprehensive variant analysis is ongoing. FACILITATE, a real-world, prospective, multicenter, European study, evaluated performance and analytical turnaround time of the Idylla™ EGFR Mutation Test compared with local reference methods. Sixteen sites obtained formalin-fixed paraffin-embedded biopsy samples with ≥ 10% neoplastic cells from patients with NSCLC. Consecutive 5 μm sections from patient samples were tested for clinically relevant NSCLC-associated <i>EGFR</i> variants using the Idylla™ EGFR Mutation Test and local reference methods; performance (concordance) and analytical turnaround time were compared. Between January 2019 and November 2020, 1,474 parallel analyses were conducted. Overall percentage agreement was 97.7% [<i>n</i> = 1,418; 95% confidence interval (CI): 96.8-98.3], positive agreement, 87.4% (<i>n</i> = 182; 95% CI: 81.8-91.4) and negative agreement, 99.2% (<i>n</i> = 1,236; 95% CI: 98.5-99.6). There were 38 (2.6%) discordant cases. Ninety percent of results were returned with an analytical turnaround time of within 1 week using the Idylla™ EGFR Mutation Test versus ∼22 days using reference methods. The Idylla™ EGFR Mutation Test performed well versus local methods and had shorter analytical turnaround time. The Idylla™ EGFR Mutation Test can thus support application of personalized medicine in NSCLC.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9190336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between radiomics features of DCE-MRI and CD8⁺ and CD4⁺ TILs in advanced gastric cancer.","authors":"Huizhen Huang,&nbsp;Zhiheng Li,&nbsp;Yue Xia,&nbsp;Zhenhua Zhao,&nbsp;Dandan Wang,&nbsp;Hongyan Jin,&nbsp;Fang Liu,&nbsp;Ye Yang,&nbsp;Liyijing Shen,&nbsp;Zengxin Lu","doi":"10.3389/pore.2023.1611001","DOIUrl":"https://doi.org/10.3389/pore.2023.1611001","url":null,"abstract":"<p><p><b>Objective:</b> The aim of this investigation was to explore the correlation between the levels of tumor-infiltrating CD8⁺ and CD4⁺ T cells and the quantitative pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with advanced gastric cancer. <b>Methods:</b> We retrospectively analyzed the data of 103 patients with histopathologically confirmed advanced gastric cancer (AGC). Three pharmacokinetic parameters, K_ep, K^trans, and V_e, and their radiomics characteristics were obtained by Omni Kinetics software. Immunohistochemical staining was used to determine CD4⁺ and CD8⁺ TILs. Statistical analysis was subsequently performed to assess the correlation between radiomics characteristics and CD4⁺ and CD8⁺ TIL density. <b>Results:</b> All patients included in this study were finally divided into either a CD8⁺ TILs low-density group (<i>n</i> = 51) (CD8⁺ TILs < 138) or a high-density group (<i>n</i> = 52) (CD8⁺ TILs ≥ 138), and a CD4⁺ TILs low-density group (<i>n</i> = 51) (CD4⁺ TILs < 87) or a high-density group (<i>n</i> = 52) (CD4⁺ TILs ≥ 87). ClusterShade and Skewness based on K_ep and Skewness based on K^trans both showed moderate negative correlation with CD8⁺ TIL levels (<i>r</i> = 0.630-0.349, <i>p</i> < 0.001), with ClusterShade based on K_ep having the highest negative correlation (<i>r</i> = -0.630, <i>p</i> < 0.001). Inertia-based K_ep showed a moderate positive correlation with the CD4⁺ TIL level (<i>r</i> = 0.549, <i>p</i> < 0.001), and the Correlation based on K_ep showed a moderate negative correlation with the CD4⁺ TIL level, which also had the highest correlation coefficient (<i>r</i> = -0.616, <i>p</i> < 0.001). The diagnostic efficacy of the above features was assessed by ROC curves. For CD8⁺ TILs, ClusterShade of K_ep had the highest mean area under the curve (AUC) (0.863). For CD4⁺ TILs, the Correlation of K_ep had the highest mean AUC (0.856). <b>Conclusion:</b> The radiomics features of DCE-MRI are associated with the expression of tumor-infiltrating CD8⁺ and CD4⁺ T cells in AGC, which have the potential to noninvasively evaluate the expression of CD8⁺ and CD4⁺ TILs in AGC patients.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10067572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}